Physicians' Academy for Cardiovascular Education

Agenda Topics ▼Video ▼Online-CME News ▼Meeting Reports Slides ▼About

ACC 2020 ▼AHA 2019 ▼Covid-19 ▼Covid-19, ACE2, RAASi ▼Diabetes & CVD ▼EAS 2019 ▼ESC 2019 ▼ESC Diabetes guidelines 2019 ▼ESC/EAS Guidelines dyslipidaemias 2019 ▼HFpEF: The essentials to know ▼Kidney disease & CVD ▼LDL-c Key Lessons ▼

Management of AFrelated stroke

Slides (presentation) - Dec. 27, 2012

Share this page with your colleagues and friends:

Continue reading:

4 Things a cardiologist should know about triglycerides

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME

The spectrum of triglyceride-containing lipoproteins

10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD

5 Things a cardiologist should know about diabetes

Slide Curriculum: Diabetes and cardiology

Slides (curriculum) - July 24, 2018

PACE Special: 5 Things a cardiologist should know about diabetes

Download - Download your free copy

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

ACS

P2Y12i monotherapy reduces net adverse clinical events in ACS patients undergoing PCI with DES

News - Apr. 9, 2020

P2Y12i monotherapy after 3 months DAPT reduces bleeding after complex PCI

News - Apr. 7, 2020

Stopping with aspirin after 3 months DAPT is safe in a wide range of patients

3' education - Apr. 2, 2020 - Prof. Freek Verheugt, MD

Atherosclerosis

High CV risk in atherosclerosis patients with highest levels of inflammatory biomarkers and LDL-c

Literature - Apr. 28, 2020 - Ridker PM, et al. - Eur Heart J 2020

Lp(a) and immune metabolism

5' education - Mar. 12, 2020 - EAS-endorsed Lp(a) satellite meeting - Jeffrey Kroon, PhD

EAS consensus statement on key biological mechanisms of LDL-c leading to ASCVD

News - Feb. 27, 2020

Atrial fibrillation

AF associated with increased CV and total mortality in East Asian HFpEF patients

Literature - May 6, 2020 - Son MK, et al. - Heart. 2020

Oral anticoagulant monotherapy reduces bleeding in AF patients after TAVI

3' education - Mar. 30, 2020 - Dr. Jur ten Berg, MD, PhD - ACC 2020

OAC alone reduces bleeding in AF patients after TAVI

News - Mar. 30, 2020

BET Inhibition

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

Primary endpoint not met for BET inhibitor in phase 3 trial

News - Sep. 30, 2019

BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?

10' education - Sep. 30, 2019 - Prof. Wouter Jukema

Covid-19

Practical recommendations for management of diabetes during COVID-19 pandemic

News - May 19, 2020

Coagulopathy in patients with COVID-19

Literature - May 19, 2020 - Levi M et al., - Lancet Haematol. 2020.

More out-of-hospital cardiac arrests during the COVID-19 outbreak in Lombardy, Italy compared to 2019

Literature - May 8, 2020 - Baldi E, et al. - N Engl J Med 2020

CV Inflammation

Pro-inflammatory activation of monocytes by elevated Lp(a) is reversible by potent Lp(a)-lowering

Literature - May 12, 2020 - Stiekema LCA et al., - Eur Heart J. 2020

High CV risk in atherosclerosis patients with highest levels of inflammatory biomarkers and LDL-c

Literature - Apr. 28, 2020 - Ridker PM, et al. - Eur Heart J 2020

PCSK9 siRNA does not affect inflammation measures or hematological parameters

Literature - Apr. 28, 2020 - Landmesser U et al., - Cardiovasc Res. 2020.

CVRM

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD

Persons with NAFLD are not automatically at high risk of acute MI or stroke

Literature - Nov. 4, 2019 - Alexander M et al, - BMJ 2019

Not only weight loss, but also maintaining a lower weight is important for a good CV risk profile

Literature - Oct. 14, 2019 - Berger SE et al., - J Am Heart Assoc. 2019

Diabetes

Icosapent ethyl reduces coronary revascularization

News - May 20, 2020

Practical recommendations for management of diabetes during COVID-19 pandemic

News - May 19, 2020

HF and CKD most frequent first CV- and renal disease manifestations in T2DM

Literature - May 18, 2020 - Birkeland KI et al., - Diabetes Obes Metab. 2020.

Diabetes & CVD

Icosapent ethyl reduces coronary revascularization

News - May 20, 2020

Practical recommendations for management of diabetes during COVID-19 pandemic

News - May 19, 2020

HF and CKD most frequent first CV- and renal disease manifestations in T2DM

Literature - May 18, 2020 - Birkeland KI et al., - Diabetes Obes Metab. 2020.

Epigenetics in CVD

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

BET inhibitor therapy did not meet primary endpoint of reducing MACE in post-ACS patients with T2DM

News - Nov. 17, 2019

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

ESC Diabetes guidelines 2019

Slides: 2019 ESC guidelines on diabetes, pre-diabetes and cardiovascular diseases - Expert insights and rationale

Slides (presentation) - Oct. 7, 2019 - Prof Francesco Cosentino, MD, Stockholm, Sweden - CME symposium held during ESC 2019

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

New ESC/EASD Guidelines on diabetes no longer regard metformin as first-line therapy

News - Sep. 3, 2019

ESC/EAS Guidelines dyslipidaemias 2019

LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

10' education - Oct. 4, 2019 - Prof. Brian Ference, MD

Slides: LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

Slides (presentation) - Sep. 9, 2019 - ESC Paris, France - Prof. Brian A. Ference, M.D, University of Cambridge, United Kingdom - CME symposium held during ESC 2019

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Paris, France - Prof. François Mach

Expert Meeting GLP-1, CVD & T2DM

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop - Online CME

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe - Online CME

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya - Online CME

Familial Hypercholesterolemia

One step closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 9, 2020 - Dirk Blom, PhD

Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH

3' education - Apr. 1, 2020 - Prof. Frederick Raal, PhD - ACC 2020

PCSK9 inhibitor reduces LDL-c in patients with HoFH

News - Apr. 1, 2020

GLP-1 RA & CVD

ESC Congress 2020 Amsterdam goes digital

News - May 6, 2020

GLP-1RA reduces BMI standard deviation score in adolescents with obesity

Literature - Apr. 28, 2020 - Kelly AS et al., - N Engl J Med. 2020.

Cardiorenal cross-talk in diabetes: The preventive challenge in DKD for GLP-1 RA

Agenda - June 8, 2020 - Online - Virtual

Heart Failure

SBP of 120-129 mmHg associated with lowest risk of outcomes in HFpEF

Literature - May 14, 2020 - Selvaraj S et al., - J Am Coll Cardiol. 2020

SGLT2i approved by FDA for treatment of HFrEF

News - May 11, 2020

AF associated with increased CV and total mortality in East Asian HFpEF patients

Literature - May 6, 2020 - Son MK, et al. - Heart. 2020

HFpEF: The essentials to know

HFpEF: Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany - Online CME

Slides: HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

Slides (presentation) - Aug. 27, 2018 - Carolyn Lam, MD - Singapore

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA - Online CME

Hypertension

Trial started with SGLT2i in COVID-19

News - May 4, 2020

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD

Inflammation Expert Opinions

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Invest in your arteries

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Kidney disease & CVD

HF and CKD most frequent first CV- and renal disease manifestations in T2DM

Literature - May 18, 2020 - Birkeland KI et al., - Diabetes Obes Metab. 2020.

Phase III trial with SGLT2i in CKD patients stopped early due to overwhelming efficacy

News - Mar. 31, 2020

Cardiorenal cross-talk in diabetes: The preventive challenge in DKD for GLP-1 RA

Agenda - June 8, 2020 - Online - Virtual

Lipids

Pro-inflammatory activation of monocytes by elevated Lp(a) is reversible by potent Lp(a)-lowering

Literature - May 12, 2020 - Stiekema LCA et al., - Eur Heart J. 2020

Triglyceride-rich lipoprotein cholesterol and small-dense LDL-c differently associated with future CV events

Literature - May 12, 2020 - Duran EK et al., - J Am Coll Cardiol. 2020.

Statin reduces total vascular events after stroke or TIA

Literature - May 6, 2020 - Szarek M, et al. - J Am Coll Cardiol. 2020

Lp(a)

Pro-inflammatory activation of monocytes by elevated Lp(a) is reversible by potent Lp(a)-lowering

Literature - May 12, 2020 - Stiekema LCA et al., - Eur Heart J. 2020

Genetically elevated Lp(a) levels associated with shorter parental life span

Literature - Mar. 17, 2020 - Arsenault BJ et al., - JAMA Netw Open. 2020

High level of ApoCIII-Lp(a) complexes together with high Lp(a) or OxPL predicts rapid progression of aortic stenosis

Literature - Feb. 26, 2020 - Capoulade R et al. - Heart 2020

PCSK9

LDL-c lowering with PCSK9i not associated with changes in cognitive functions

Literature - May 18, 2020 - Gencer B et al., - J Am Coll Cardiol. 2020.

Pro-inflammatory activation of monocytes by elevated Lp(a) is reversible by potent Lp(a)-lowering

Literature - May 12, 2020 - Stiekema LCA et al., - Eur Heart J. 2020

ESC Congress 2020 Amsterdam goes digital

News - May 6, 2020

Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension: Key questions addressed

Online-CME - This course consists of 3 separate lectures

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA - Online CME

Novel insights in the management and prognosis of pulmonary hypertension

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Stroke

Drinking filtered coffee associated with lower mortality

Literature - May 18, 2020 - Tverdal A et al., - Eur J Prev Cardiol. 2020.

AF associated with increased CV and total mortality in East Asian HFpEF patients

Literature - May 6, 2020 - Son MK, et al. - Heart. 2020

Statin reduces total vascular events after stroke or TIA

Literature - May 6, 2020 - Szarek M, et al. - J Am Coll Cardiol. 2020

© 2006 - 2020 pace-cme.org - About